Qubit Pharmaceuticals
Qubit Pharmaceuticals develops quantum- and AI-enabled molecular modeling software and drug discovery programs for oncology, inflammation, and antivirals.
- Technology
- Quantum-enabled molecular simulation and drug discovery software/platform with hybrid HPC-QC capabilities.
- Headquarters
- Paris
- Founded
- 2021
- Ownership
- Private company
- Funding
- The company website states that it has raised more than $25 million.
- Products and platforms
- ATLAS
- Key people
- Robert Marino, PhD, CEO
Dr Louis Lagardère, Research Engineer, Sorbonne Université; founder
Pr J.-P. Piquemal, CSO at Qubit Pharmaceuticals, Professor of Theoretical Chemistry, Sorbonne Université; founder
Pr Matthieu Montes, Professor of Bioinformatics, Cnam; founder - Website
- qubit-pharmaceuticals.com
Qubit Pharmaceuticals says it applies quantum physics, artificial intelligence, and computational chemistry to molecular design and drug discovery. Its website describes the company as developing treatments for major diseases while also offering a platform for high-precision molecular simulation and molecule generation. The company presents this work as quantum-aided drug discovery, with hybrid HPC-QC capabilities and a focus on solving chemistry problems with high accuracy.
The company names ATLAS as its quantum-, AI-, and physics-inspired platform for molecular modeling. According to the site, ATLAS was integrated since the company’s inception in 2021 and supports simulation, modeling, and molecule generation. Qubit Pharmaceuticals also states that it has offices in Paris, Boston, and Chicago, more than 60 employees, and over $25 million raised. Its project pipeline includes internal and partnered programs, with therapeutic emphasis on oncology, inflammation, and antiviral applications.
Sources
Facts on this page come from the sources below, retrieved by DesignQuantum.
- Qubit Pharmaceuticals qubit-pharmaceuticals.com
Last verified: October 28, 2026